Maricann Group (CNSX:MARI – Free Report) had its price target boosted by National Bankshares from $13.25 to $15.00 in a research report released on Thursday,BayStreet.CA reports.
Separately, Royal Bank Of Canada lifted their price objective on shares of Maricann Group from $6.00 to $16.00 in a research note on Wednesday, December 10th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Maricann Group currently has an average rating of “Buy” and a consensus target price of $14.10.
Maricann Group Stock Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients. The Company is undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.
Read More
- Five stocks we like better than Maricann Group
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- Buy This Stock at 9:30 AM on MONDAY!
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
